Invivyd, Inc. 8-K

What Happened

• On January 8, 2026, Invivyd, Inc. announced via press release (filed on Form 8-K, Item 2.02/8.01) preliminary fourth-quarter 2025 results that include estimated PEMGARDA® (pemivibart) net product revenue and the company’s cash and cash equivalents as of December 31, 2025.
• The figures released are preliminary management estimates, have not been audited, and are subject to change upon completion of the company’s quarter- and year-end close and finalization of the financial statements.

Key Details

• Date of disclosure: January 8, 2026.
• Metrics disclosed: preliminary Q4 2025 PEMGARDA net product revenue and cash & cash equivalents as of Dec 31, 2025.
• Qualification: Preliminary data prepared by management; not audited by the independent registered public accounting firm and subject to revision.
• Materials filed with the 8-K: the press release and a corporate presentation (Exhibits 99.1 and 99.2).

Why It Matters

• These preliminary revenue and cash figures give investors an early view of Invivyd’s quarterly sales performance for PEMGARDA and near-term liquidity, which can influence investor expectations ahead of final financial statements.
• Because the numbers are unaudited and provisional, investors should treat them as preliminary and wait for the completed, audited year-end financial statements for a definitive assessment.